COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

All | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 1 - 20 of 197
First Large-scale, Multicenter Proteogenomic Analysis Offers New Insights Into Pediatric Brain Tumor Biology

Data reported can guide new therapeutic avenues for pediatric patients

A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately identify different types of tumors and methods for treating them.


Proteogenomics Enhances the Identification of Therapeutic Vulnerabilities in Breast Cancer

Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard and other institutions have applied powerful proteogenomics approaches to better understand the biological complexity of breast cancer.


Evaluating Biomarkers in Metastatic Breast Cancer Bone Biopsies Without Decalcification

In a recent publication in the journal Clinical Chemistry,  CPTAC investigators from Fred Hutchinson Cancer Research Center described a robust technique for evaluating biomarker expression of key receptors in patients with breast cancer bone metastasis using non-decalcified bone biopsies in imm


CPTAC Study Identifies Unique Linkage of Glycosylation to Ovarian Cancer

Protein glycosylation, the enzymatic process that attaches glycans or sugar molecules to proteins, plays a crucial role in cancer development processes, such as cell-cell adhesion, cell growth, ligand-receptor binding, and tumor metastasis. Aside from phosphorylation, other protein modifications have not been investigated in large-scale proteomic studies.


Improved BASIL Workflow Provides Precise and Robust Protein Profiling for Single-Cell Analysis

Almost 18 months ago, CPTAC researchers from theIntegrative Omics Group at Pacific Northwest National Laboratory (PNNL), developed a stream-lined technique to increase the sensitivity of peptide phospho-group identification during mass spectral analysis.  The solution, called the ‘


In Case You Missed It: CPTAC Junior Investigator Spotlight (Part 1)

In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr.


New Proteogenomic Data Release for CPTAC Lung Squamous Cell Carcinoma Discovery Study!

Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study!  Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer


AutoRT - Using Peptide Retention Time Prediction to Accurately Determine Quality of Peptide Identification

In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications.  Using a deep learning algorithm, the software


The CPTAC Virtual Symposium - Sept 22, 2020

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020.    This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies for pediatric brain cancer, acute myeloid leukemia,


SBIR Proteomics Technologies Funding Announcement: Single-Cell Unbiased Discovery

The NCI’s Small Business Innovation Research (SBIR) Development Center has released a program solicitation (PHS 2021-1) which includes a new, Clinical Proteomic Tumor Analysis Consortium (CPTAC)-inspired grant.  The announcement calls for the development of hig


In Case You Missed It: CPTAC Investigator Spotlight on David Fenyö and Emily Kawaler

This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work.  In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and researcher Emily Kawaler!


Fred Hutch Team Establishes a New CLIA Lab for Running Targeted-MS assays, Including a Novel CLIA-Approved HER2 Test

A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer.  Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have achieved an important milestone in this regard, by establishing a Clinical Laboratory Improvement Amendments (CLIA) - certified laboratory for running targeted proteomic assays based on multiple reaction monitoring (MRM) mass spectrometry (MS).


Lung Adenocarcinoma (LUAD) Discoveries from two NCI Proteomics Consortia

Two new studies released July 9th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before.


OCCPR Webinar: MSFragger

Join Dr. Alexey Nesvizhskii, Professor of Pathology and Computational Medicine & Bioinformatics at University of Michigan, as he speaks on our next OCCPR Webinar about his ultrafast MSFragger software.  The webinar will take place on Wednesday, July 15th at 1pm - registration is free, but required.


In Case You Missed It: CPTAC Investigator Spotlight on Karin Rodland

The Investigator Spotlight Series was the brain child of Dr. Dawn Hayward, an NCI Communications Fellow at OCCPR, to highlight our CPTAC researchers and thier work.  In case you missed it the first time, here she features CPTAC scientist Dr. Karin Rodland.  Enjoy!


CPTAC At AACR Virtual Meeting II

We are so excited to be a part of the AACR Virtual Meeting II, June 22-24, 2020


Proteomics 3 Ways – An Efficient Analysis of Global, Glyco-, and Phospho-Proteomics

In a new study published in Analytical Chemistry, we see another example of ingenuity by NCI’s Office of Cancer Clinical Proteomic Research (OCCPR) Clinical Proteomic Tumor Analysis Consortium (CPTAC) scientists.  In an effort to optimize analytical output and conserve hard-to-obtain biospecimen samples, CPTAC researchers out of John Hopkins School of Medicine


Joint Proteomic and Genomic Data Release for Head and Neck Squamous Cell Carcinoma

108 cases of the NCI’s Clinical Proteomic Tumor Analysis Program (CPTAC) Head and Neck Squamous Cell Carcinoma Discovery Study have been proteomically and genomically profiled!  Each case includes HPV-negative, treatment naive and normal adjacent tissue, and includes proteomic ad phosphoproteomic data on the Proteomic Data Commons (PDC), as well as RNA-Seq, miRNA-Seq, WGS, WXS genomic data on the


50 New AML Pathology Slides on TCIA-CPTAC Pathology Portal

50 new pathology slides from 33 new Acute Myeloid Leukemia (AML) subjects are now available on the TCIA-CPTAC Pathology Portal. The April 2020 image release brings the total number of AML pathology slides to 120 from 88 subjects, with most of them also having both tumor blood and marrow imaging. 


Pages